Johnson & Johnson (NYSE:JNJ) EVP Sells $62,928.45 in Stock

Johnson & Johnson (NYSE:JNJ) EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded down $1.11 on Tuesday, reaching $155.04. 9,669,278 shares of the company were exchanged, compared to its average volume of 9,047,775. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The firm has a market cap of $373.27 billion, a price-to-earnings ratio of 23.31, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The company has a 50-day moving average of $148.00 and a 200-day moving average of $155.91.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the prior year, the company posted $2.29 EPS. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.20%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Analyst Ratings Changes

Several brokerages have recently weighed in on JNJ. Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Stifel Nicolaus reduced their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Bank of America reduced their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Hedge Funds Weigh In On Johnson & Johnson

A number of institutional investors and hedge funds have recently made changes to their positions in JNJ. IFS Advisors LLC grew its stake in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares during the last quarter. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $29,000. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $31,000. Finally, Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $32,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.